Liver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus/Human Immunodeficiency Virus Coinfection

Open Forum Infectious Diseases

Volumn 4, Issue 3, 2017, Pages

  Boesecke, Christoph ^a,b   Ingiliz, Patrick ^c   Berger, Florian ^d   Lutz, Thomas ^e   Schewe, Knud ^f   Zur Wiesch, Julian Schulze ^b,g   Baumgarten, Axel ^c   Christensen, Stefan ^h   Rockstroh, Jürgen K ^a,b   Mauss, Stefan ^d  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c Center for Infectiology (CIB)   (Germany)

^d Center for HIV and Hepatogastroenterology   (Germany)

^e Infektiologikum   (Germany)

^f Infektionsmedizinisches Centrum Hamburg   (Germany)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h CIM Infectious diseases   (Germany)

Author keywords

chronic hepatitis C; DAA; HCV treatment; HCV HIV coinfection

Indexed keywords

EID: 85045286163     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/OFID/OFX158     Document Type: Article

References (11)

1. Sulkowski MS. HCV-HIV co-infected patients: no longer a 'special' population? Liver Int 2016; 36(Suppl 1):43-6.
2. Naggie S, Muir AJ. Oral combination therapies for hepatitis C virus infection: successes, challenges, and unmet needs. Annu Rev Med 2017; 68:345-58.
3. European AIDS Clinical Society. EACS Guidelines 8.1. Available at: http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html. Accessed 18 December 2016.
4. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. Available at: http://www.easl.eu/research/our-contributions/clinical-practice-guidelines/detail/easl-recommendations-on-treatment-of-hepatitis-c-2016. Accessed 18 December 2016.
5. American Association for the Study of Liver Diseases (AASLD). HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Available at: http://www.hcvguidelines.org. Accessed 18 December 2016.
6. Arias A, Aguilera A, Soriano V, et al. Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials. Antivir Ther 2016. doi: 10.3851/IMP3061.
7. Neukam K, Suárez-Santamaría M, Rivero-Juárez A, et al. HIV coinfection impairs the response to DAA-based HCV therapy. In: 51st EASL; April 13-17, 2016 (Abstract LBP513); Barcelona, Spain.
8. d'Arminio Monforte A, Cozzi-Lepri A, Ceccherini-Silberstein F, et al. Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: data from the Icona cohort. PLoS One 2017; 12:e0177402.
9. Gil-Martin A, Gonzalez-García JJ, Cruz-Martos E, et al. Real-world outcomes with new HCV antivirals in HIV/HCV-coinfected subjects: Madrid Coinfection Registry(Madrid-CoRE) findings. In: 67th Annual Meeting of the American Association for the Study of Liver Diseases; November 11-15, 2016 (Abstract 78); Boston, Massachusetts.
10. Rockstroh J, Lutz T, Mauss S, et al. SVR12 rates under DAA-based HCV therapy from the National German Cohort Study: does HIV co-infection impair the response to DAA combination therapy? In: 67th Annual Meeting of the American Association for the Study of Liver Diseases; November 11-15, 2016 (Abstract 907); Boston, Massachusetts.
11. Naggie S, Rosenthal E, Kattakuzhy S, et al. Real world effectiveness of ledipasvir/sofosbuvir (LDV/SOF) in patients coinfected with HCV and HIV-1: a comparative analysis of clinical trials with four real world cohorts. In: 67th Annual Meeting of the American Association for the Study of Liver Diseases; November 11-15, 2016 (Abstract 898); Boston, Massachusetts.